Online inquiry

IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5474MR)

This product GTTS-WQ5474MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets tcdB gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_003434531.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299394
UniProt ID P18177
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5474MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4974MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ3208MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ7768MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ2734MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ5264MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ11004MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ15845MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ9698MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW